- Home
- PETS vs HOWL Comparison
PETS vs HOWL Comparison
Compare PETS & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PETS
- HOWL
- Stock Information
- Founded
- PETS 1996
- HOWL 2017
- Country
- PETS United States
- HOWL United States
- Employees
- PETS N/A
- HOWL N/A
- Industry
- PETS Retail-Drug Stores and Proprietary Stores
- HOWL Biotechnology: Pharmaceutical Preparations
- Sector
- PETS Consumer Staples
- HOWL Health Care
- Exchange
- PETS Nasdaq
- HOWL Nasdaq
- Market Cap
- PETS 98.6M
- HOWL 87.4M
- IPO Year
- PETS N/A
- HOWL 2021
- Fundamental
- Price
- PETS $5.11
- HOWL $1.33
- Analyst Decision
- PETS Sell
- HOWL Strong Buy
- Analyst Count
- PETS 2
- HOWL 2
- Target Price
- PETS $3.50
- HOWL $9.50
- AVG Volume (30 Days)
- PETS 249.5K
- HOWL 331.1K
- Earning Date
- PETS 02-06-2025
- HOWL 03-06-2025
- Dividend Yield
- PETS N/A
- HOWL N/A
- EPS Growth
- PETS N/A
- HOWL N/A
- EPS
- PETS N/A
- HOWL N/A
- Revenue
- PETS $259,343,000.00
- HOWL $3,386,000.00
- Revenue This Year
- PETS N/A
- HOWL N/A
- Revenue Next Year
- PETS $3.36
- HOWL $34.17
- P/E Ratio
- PETS N/A
- HOWL N/A
- Revenue Growth
- PETS N/A
- HOWL N/A
- 52 Week Low
- PETS $2.90
- HOWL $1.31
- 52 Week High
- PETS $7.24
- HOWL $8.19
- Technical
- Relative Strength Index (RSI)
- PETS 52.60
- HOWL 33.77
- Support Level
- PETS $4.74
- HOWL $1.50
- Resistance Level
- PETS $5.30
- HOWL $1.72
- Average True Range (ATR)
- PETS 0.24
- HOWL 0.11
- MACD
- PETS 0.02
- HOWL -0.00
- Stochastic Oscillator
- PETS 65.06
- HOWL 4.88
About PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.